|
Acute gastroenteritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
BCS was diagnosed during the course of an episode of acute gastroenteritis with dehydration.
|
22452639 |
2012 |
|
Factor V Leiden mutation
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Factor V Leiden mutation is frequently found in patients with BCS and prothrombin gene variant is seen more frequently in PVT.
|
23123534 |
2012 |
|
Hypertension in children
|
0.010 |
Biomarker
|
disease |
BEFREE |
BCS is a rare form of portal hypertension in children.
|
22452639 |
2012 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
We evaluated the cellular uptake of KLA fused to TCTP-PTD (hereafter called TCTP-KLA) and its effect on cancer cell viability.
|
21565400 |
2011 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Monitoring of the minimal residual disease load with quantitative real-time PCR can be performed for NPM1 and MLL-PTD-mutated cases.
|
20805748 |
2010 |
|
Malignant transformation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Estrogen combined with PTD-HPV18E7(DeltaRB) enhanced cell proliferation rate, induced genomic instability, including abnormal centrosome duplication and chromosomal instability, and exhibited malignant transformation with anchorage-independent growth.
|
20009582 |
2010 |
|
Neonatal disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Screening of BCS1L mutations in severe neonatal disorders suspicious for mitochondrial cause.
|
18386115 |
2008 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy.
|
16930946 |
2006 |
|
Leukemogenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Since also present in the stem cell subfraction, these factors seem not to be major determinants in MLL-PTD leukemogenesis.
|
16540167 |
2006 |
|
Iron Overload
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L.
|
12215968 |
2002 |
|
Myeloproliferative disease
|
0.020 |
Biomarker
|
group |
BEFREE |
To synthesize the prevalence of CALR mutations according to the different types (i.e., Budd-Chiari syndrome [BCS] and portal vein thrombosis [PVT]) and characteristics (i.e., with and without myeloproliferative neoplasms [MPNs] and JAK2V617F mutation) of SVT patients.
|
29803161 |
2018 |
|
Myeloproliferative disease
|
0.020 |
Biomarker
|
group |
BEFREE |
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
|
30431598 |
2018 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Patients with a history of PTD did not have an increased risk of later being diagnosed with female malignancies.
|
27614746 |
2017 |
|
Encephalopathies
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Recently, patients with early liver failure, renal tubulopathy and encephalopathy due to the mutations in the BCS1L gene coding for a structural protein in mitochondrial complex III have been described.
|
23892085 |
2013 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
We evaluated the cellular uptake of KLA fused to TCTP-PTD (hereafter called TCTP-KLA) and its effect on cancer cell viability.
|
21565400 |
2011 |
|
Encephalopathies
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Here, we report BCS1L mutations in six patients, from four unrelated families and presenting neonatal proximal tubulopathy, hepatic involvement and encephalopathy.
|
11528392 |
2001 |
|
Noninfiltrating Intraductal Carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Among women with DCIS, those at risk for MDD were more likely to receive BCS (adjusted odds ratio [AOR] 2.04, 95% CI 1.04-4.00, p = 0.04) or mastectomy (AOR 1.88, 95% CI 0.91-3.86, p = 0.09) compared to BCS + RT.
|
30406869 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Primary surgical lumpectomy with negative margins followed by WBI seems to be the treatment of choice in DCIS treated with BCS with respect to IBTR.
|
30118902 |
2018 |
|
Noninfiltrating Intraductal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Adjuvant HT use in ER+ DCIS has increased over time, with the highest rates in patients treated with BCS and radiation.
|
28766214 |
2017 |
|
Adenocarcinoma of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
We have established a butyrate-resistant human colon adenocarcinoma cell line (BCS-TC2.BR2) from nontumorigenic BCS-TC2 cells to analyze whether the acquisition of such phenotype confers resistance to apoptosis and stress.
|
15231671 |
2004 |
|
Adenocarcinoma of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
Fibronectin (FN) modulates the behavior of the poorly differentiated, human colon adenocarcinoma-derived BCS-TC2 cells by promoting adhesion through the alpha(5)beta(1)-integrin, as this effect is blocked by anti-alpha(5) and beta(1 )chain antibodies.
|
12138246 |
2002 |
|
Adenocarcinoma of colon
|
0.030 |
Biomarker
|
disease |
BEFREE |
A new cell line designated as BCS-TC2 was established in culture from a primary human colon adenocarcinoma.
|
1366654 |
1990 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
PTD activity in vivo shown in 1 could significantly reduce the growth of A549 xenografted tumor, without obvious loss of mice body weight.
|
30710171 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
After discussion among our multidisciplinary tumor board, we felt this patient to be suitable for BCS and IORT given his age, favorable tumor subtype, size, and clinically early stage breast cancer.
|
28597470 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Combinatorial targeting of EGF-Receptor (EGFR) and Akt2, but not Ak1 or Akt3, by PTD-DRBD delivered siRNAs synergized to induce tumor cell specific apoptosis.
|
19901546 |
2009 |